TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25661407

Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling to reduce total cholesterol concentration
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (familial risk children)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Children with high Lp(a) concentrations (>500 mg/L) in the intervention group
Number of subjects: 1062
Study: 23484827

Group type: EXPERIMENTAL
Intervention: Family presence during CPR (intervention group)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Standard practice regarding family presence (control group)
Number of subjects: 570
Study: 20857138

Group type: EXPERIMENTAL
Intervention: MOCP users tested at Day 1 and Day 14 of their cycle
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-MOCP users tested at menstruation and ovulation
Number of subjects: 38
Study: 18204335

Group type: EXPERIMENTAL
Intervention: Aripiprazole (initiated at 10 mg/d, flexibly dosed at 5-30 mg/d)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 16728480

Group type: EXPERIMENTAL
Intervention: Concurrent radiochemotherapy (RT-CT) - two cycles of platinum etoposide followed by two cycles of platinum-vinorelbine
Number of subjects: 173

Group type: COMPARATOR
Intervention: Sequential radiochemotherapy (RT-CT) - three cycles of chemotherapy followed by radiotherapy
Number of subjects: 173
Study: 12410708

Group type: EXPERIMENTAL
Intervention: Cleo Performance lamps (conventional UV A lamps)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cleo Natural lamps (new higher UV B-emitting lamps)
Number of subjects: 34
Study: 9892032

Group type: EXPERIMENTAL
Intervention: HFA-134a albuterol sulfate (108 microg of albuterol sulfate, equivalent to 90 microg of albuterol base)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CFC albuterol (equivalent doses)
Number of subjects: 22
Study: 8655205

Group type: EXPERIMENTAL
Intervention: Imipenem (3 x 0.5g/d)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Cefotaxime (3 x 2g/d) plus Piperacillin (3 x 4g/d)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 165

Group type: COMPARATOR
Intervention: Cefotaxime plus Piperacillin
Number of subjects: 165
Study: 2363736

Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (27 mg/kg EPA and 18 mg/kg DHA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-dose fish oil (54 mg/kg EPA and 36 mg/kg DHA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Olive oil (6.8 gm of oleic acid)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All groups (low-dose, high-dose, and olive oil)
Number of subjects: 49
Study: 348096

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 22
Study: 31750698

Group type: EXPERIMENTAL
Intervention: GOAL (goal prompts/support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRACK (self‐monitoring of alcohol use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PLAN (feedback on drinking plans and DD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: USE (postdrinking feedback on alcohol consumed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: COMBO (i.e., 4 interventions combined)
Number of subjects: 0
Study: 28294700

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control Sedentary (SED)
Number of subjects: 10
Study: 26725184

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Erlotinib (150 mg orally daily on days 2-16) plus Carboplatin (AUC=5 on day 1) and Paclitaxel (200 mg/m2 intravenously on day 1) followed by Erlotinib (150 mg orally)
Number of subjects: 59
Study: 25332253

Group type: EXPERIMENTAL
Intervention: Proton radiotherapy with chemotherapy (vincristine, actinomycin, and cyclophosphamide or vincristine, actinomycin, and ifosfamide)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Proton radiotherapy with chemotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Number of subjects: 57
Study: 21823052

Group type: EXPERIMENTAL
Intervention: Physical activity (training group) - 3 fast 30-min walks and 1 or 2 1-h aerobic training sessions per week
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sedentary life (controls)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Physical activity (training group)
Number of subjects: 112
Study: 21073365

Group type: EXPERIMENTAL
Intervention: ICD plus CRT
Number of subjects: 1798

Group type: COMPARATOR
Intervention: ICD alone
Number of subjects: 1798
Study: 17393377

Group type: EXPERIMENTAL
Intervention: Weight reduction through reduced energy intake
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-fat diet with no change in energy intake (isoenergetic)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group with no dietary change from habitual intake
Number of subjects: 64
Study: 16301719

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Contrast computed tomography (CT)
Number of subjects: 29
Study: 12003920

Group type: EXPERIMENTAL
Intervention: At-risk drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light-moderate drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: At-risk drinkers vs. light-moderate drinkers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-at-risk drinkers in occupational medicine vs. primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: At-risk drinkers in occupational medicine vs. primary care
Number of subjects: 0
Study: 9528868

Group type: EXPERIMENTAL
Intervention: Pre-contrast MR images
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pre-contrast MR images plus post-contrast MR images
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pre-contrast MR images plus post-contrast plus fast dynamic MR imaging
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fast dynamic MR imaging
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clinical staging
Number of subjects: 42
Study: 7886126

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (1000 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate (1500 mg daily, 50% higher than erythromycin estolate)
Number of subjects: 12
Study: 2219563

Group type: COMPARATOR
Intervention: EMLA cream (lidocaine-prilocaine), applied for 60 minutes
Number of subjects: 90

Group type: COMPARATOR
Intervention: EMLA cream (lidocaine-prilocaine), applied for over 90 minutes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo, applied for 60 minutes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo, applied for over 90 minutes
Number of subjects: 90
Study: 77140

Group type: EXPERIMENTAL
Intervention: Quinidine gluconate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quinidine sulfate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31289905

Group type: EXPERIMENTAL
Intervention: rhFGF13A
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhFGF13B
Number of subjects: 0
Study: 28521199

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Diacetylmorphine
Number of subjects: 202
Study: 26044714

Group type: EXPERIMENTAL
Intervention: Real acupuncture needles
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham acupuncture needles
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Touch sense
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Vision sense
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of touch and vision
Number of subjects: 63
Study: 24522442

Group type: EXPERIMENTAL
Intervention: 800 mg DHA/d (treatment)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 185
Study: 22933033

Group type: EXPERIMENTAL
Intervention: Hydrogel spacer (SP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 3D conformal radiotherapy (3DCRT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 84
Study: 19536012

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17697170

Group type: EXPERIMENTAL
Intervention: Chemically modified chitosan (CL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmodified chitosan (UC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chitosan adsorption
Number of subjects: 0
Study: 15182773

Group type: EXPERIMENTAL
Intervention: Carvedilol (target 25 mg bid)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Enalapril (target 10 mg bid)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Combination of carvedilol and enalapril
Number of subjects: 572

Group type: COMPARATOR
Intervention: All groups (combination, carvedilol, enalapril)
Number of subjects: 572
Study: 12515648

Group type: EXPERIMENTAL
Intervention: Continuous tourniquet application throughout the operation (A group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (B group)
Number of subjects: 79
Study: 10591429

Group type: EXPERIMENTAL
Intervention: Premature infants < or = 32 wk
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Premature infants > 32 wk
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Premature infants < or = 32 wk at 4 mo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Premature infants > 32 wk at 4 mo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Premature infants < or = 32 wk at 6 mo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Premature infants > 32 wk at 6 mo
Number of subjects: 85

Group type: COMPARATOR
Intervention: Term infants at 6 mo
Number of subjects: 85

Group type: COMPARATOR
Intervention: Comparison between term infants and premature groups
Number of subjects: 85
Study: 1907432

Group type: EXPERIMENTAL
Intervention: 20 infusions of Na2EDTA
Number of subjects: 153

Group type: COMPARATOR
Intervention: 20 infusions of saline
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Na2EDTA
Number of subjects: 153

Group type: COMPARATOR
Intervention: saline
Number of subjects: 153
Study: 6135253

Group type: EXPERIMENTAL
Intervention: Beta-blockade maintained with 100 mg metoprolol per os two hours before surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Beta-blockade withdrawn three days preoperatively
Number of subjects: 29
Study: 30471264

Group type: EXPERIMENTAL
Intervention: Postabortion contraception use
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prior use of contraception
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intention to use postabortion contraception
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Increased number of children
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Occupation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Abortion method
Number of subjects: 500
Study: 28173788

Group type: EXPERIMENTAL
Intervention: Hip-focused biofeedback
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Knee-focused biofeedback
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham biofeedback
Number of subjects: 150
Study: 27122150

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate supplementation (25,000 IU daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23712672

Group type: EXPERIMENTAL
Intervention: Plate osteosynthesis (ORIF group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intramedullary nailing (IMN group)
Number of subjects: 67
Study: 22341790

Group type: EXPERIMENTAL
Intervention: Electrocardiographic criteria (Sokolow-Lyon and Cornell)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon-1
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon-2
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Cornell criteria
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Any of the 3 electrocardiographic criteria
Number of subjects: 645
Study: 20515440

Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18936041

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI) using radiofrequency (RF) current (35W, 48 degrees C) with a 3.5 mm open irrigated tip catheter (Navistar Thermocool).
Number of subjects: 46
Study: 15730048

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dipyridamole 5 mg/kg
Number of subjects: 36
Study: 12517683

Group type: EXPERIMENTAL
Intervention: GRD 360 mg administered once-daily at bedtime (10 PM)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: GRD 240 mg and higher administered once-daily at bedtime
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: All GRD groups (including 540 mg and 240 mg)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: GRD 540 mg administered once-daily at bedtime
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478

Group type: COMPARATOR
Intervention: GRD 360 mg administered once-daily at 8 AM
Number of subjects: 478
Study: 10379127

Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hysteroscopy and curettage
Number of subjects: 0
Study: 9402265

Group type: EXPERIMENTAL
Intervention: Continuation of daily GnRHa injections for 15 days after HCG administration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Disruption of daily GnRHa injections at the day of HCG administration
Number of subjects: 38
Study: 8228208

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once a day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once a day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and lisinopril (once a day)
Number of subjects: 15
Study: 3943269

Group type: EXPERIMENTAL
Intervention: Nalmefene 2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nalmefene 6 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nalmefene 12 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nalmefene 24 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nalmefene (all doses)
Number of subjects: 6
Study: 30051365

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 97
Study: 26558919

Group type: EXPERIMENTAL
Intervention: Iron deficiency and anemia
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Iodine deficiency
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Urinary iodine excretion
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Blood hemoglobin level
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Serum iron
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Total iron binding capacity
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Transferrin saturation
Number of subjects: 759
Study: 25330122

Group type: EXPERIMENTAL
Intervention: aprepitant + paroxetine
Number of subjects: 236

Group type: COMPARATOR
Intervention: paroxetine + placebo
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: aprepitant + placebo
Number of subjects: 236
Study: 23190131

Group type: EXPERIMENTAL
Intervention: NPCT group visits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19786730

Group type: EXPERIMENTAL
Intervention: Information group (attended lecture and received booklet)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control group (did not attend lecture)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Information group
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 475
Study: 18828196

Group type: EXPERIMENTAL
Intervention: Intensive plasma exchange (PEx); median duration 12 days (range 4-28 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10
Study: 16077402

Group type: EXPERIMENTAL
Intervention: High tidal volume/low positive end-expiratory pressure (10-12 mL/kg and 2-3 cm H2O)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low tidal volume/high positive end-expiratory pressure (8 mL/kg and 10 cm H2O)
Number of subjects: 40
Study: 12123423

Group type: EXPERIMENTAL
Intervention: Caspofungin acetate
Number of subjects: 623
Study: 10076936

Group type: EXPERIMENTAL
Intervention: Gliding nail
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gamma nail
Number of subjects: 80
Study: 8745670

Group type: EXPERIMENTAL
Intervention: Granisetron (G) 3 mg intravenously before chemotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ondansetron (O) 8 mg intravenously, followed by 8 mg orally every eight hours for the next three days
Number of subjects: 150
Study: 2011253

Group type: EXPERIMENTAL
Intervention: Cop 1
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 6753090

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen administered as a single dose at night
Number of subjects: 0

Group type: COMPARATOR
Intervention: 250 mg naproxen administered twice daily
Number of subjects: 0
Study: 30946523

Group type: EXPERIMENTAL
Intervention: ADT+EBRT
Number of subjects: 263

Group type: COMPARATOR
Intervention: ADT
Number of subjects: 263
Study: 30181666

Group type: EXPERIMENTAL
Intervention: Early discharge (within 48-72 hours of admission)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard discharge (after 72 hours)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard discharge
Number of subjects: 151
Study: 28754903

Group type: EXPERIMENTAL
Intervention: Pirenoxine eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0
Study: 25681464

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 3623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3623
Study: 23574579

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LMWH followed by warfarin (INR of 2.0-3.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: LMWH followed by warfarin
Number of subjects: 0
Study: 21507585

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus bupropion
Number of subjects: 148

Group type: COMPARATOR
Intervention: Nicotine patch plus placebo
Number of subjects: 148
Study: 19585106

Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin reuptake inhibitor) for 7-10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17763613

Group type: EXPERIMENTAL
Intervention: Combined treatment with fractional resurfacing and ALA-PDT
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fractional resurfacing alone
Number of subjects: 4
Study: 14994406

Group type: EXPERIMENTAL
Intervention: 5% ibuprofen cream applied in a 10-cm strip tid for 7 days (approximately 200 mg ibuprofen per strip)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 5% ibuprofen cream
Number of subjects: 225
Study: 11483076

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 291
Study: 9481194

Group type: EXPERIMENTAL
Intervention: Intrapartum amnioinfusion (AI) with 0.9% normal saline at 15 ml/min until a volume of 11 was completed, repeated if delivery did not occur within 4 hours.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrapartum amnioinfusion (AI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard methods (control group)
Number of subjects: 60
Study: 7993831

Group type: EXPERIMENTAL
Intervention: granisetron 1 mg bd orally for 7 days
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: granisetron 1 mg bd orally for 7 days plus prophylactic dexamethasone (12 mg i.v.) on the first day only
Number of subjects: 357

Group type: COMPARATOR
Intervention: metoclopramide (3 mg/kg i.v. loading dose; 4 mg/kg i.v. infusion) plus dex (12 mg i.v.) on the first day followed by met 10 mg orally tds for a further 6 days
Number of subjects: 357
Study: 2544431

Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (50 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (100 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (200 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (100 mg) after 15 days
Number of subjects: 6
Study: 29664999

Group type: EXPERIMENTAL
Intervention: Fibrin sealant patch (patch group)
Number of subjects: 142

Group type: COMPARATOR
Intervention: No patch (control group)
Number of subjects: 142
Study: 28753230

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Mailings with call-in number for colonoscopy and mailed fecal tests (arm 2)
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Mailings plus brief telephone assistance (arm 3)
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Mailings and assistance plus nurse navigation (arm 4)
Number of subjects: 4675
Study: 26141683

Group type: EXPERIMENTAL
Intervention: FOLFIRI-cetuximab followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A)
Number of subjects: 500

Group type: COMPARATOR
Intervention: OPTIMOX-bevacizumab followed by irinotecan-based second-line chemotherapy with bevacizumab and anti-EGFR monoclonal antibody (Arm B)
Number of subjects: 500
Study: 23218563

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 21139151

Group type: EXPERIMENTAL
Intervention: Candidate vaginal microbicide gel containing cellulose acetate 1,2‐benzenedicarboxylate in a glycerol‐based vehicle
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Candidate vaginal microbicide gel
Number of subjects: 5
Study: 18417521

Group type: EXPERIMENTAL
Intervention: Rapid polymerase chain reaction based screening test for MRSA
Number of subjects: 6888

Group type: COMPARATOR
Intervention: Conventional culture
Number of subjects: 6888